Issues related to pain management.; Issues related to pain management.; Issues related to pain management.; Issues related to pain management.
Registered Lobbyists (2)
HAZEN MARSHALL ●NEW— Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don NicklesMONICA POPP ●NEW— Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint
IDs
Filing UUID:ae6090a1-0bc2-4ba7-acbc-72f04dc0a493
Registrant ID:401105121
Client ID:65129
2025-03-24
BECKER & POLIAKOFF, P.A.
JOHNSON & JOHNSON SERVICES, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
pharmaceutical, biotechnology, and medical technologies issues
Registered Lobbyists (2)
NERI MARTINEZ ●NEW— Staff Director, Senate Special Committee on Aging Committee; Chief of Staff, Sen. Tim Scott; Chief of Staff, Dept. of Energy Office of Economic ImpactOMAR FRANCO ●NEW— Chief of Staff, Rep. Mario Diaz-Balart
IDs
Filing UUID:e6e392ff-e18c-466c-a170-c4be6351a227
Registrant ID:283696
Client ID:65151
2025-03-20
BGR GOVERNMENT AFFAIRS
DIGNITY AND WELLNESS PATIENT SOLUTIONS, LLC
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Provide strategic counsel and advocate on issues related to providing LTC pharmacy services
Registered Lobbyists (3)
CHRIS KELLY ●NEW— Health Policy Dir., Leg. Asst., Leg. Corr., Front Office Coordinator, Staff Asst. Sen. BlackburnJOEL BAILEY ●NEW— COS Rep. Panetta; LD Rep. Ashford; LD Rep. Matheson; Sr. LA Rep. Matsui; LA, Sr. LA Rep. Baron Hill; Intern Rep. RahallRAGHAV AGGARWAL ●NEW— Health Insurance Specialist, CMS; Senior Health Advisor (Detailee), Senate Finance Committee/Sen. Ron Wyden; Social Science Research Analyst, CMS; Intern, Sen. Feinstein; Secretarys Fellow, US Dept. of Interior
IDs
Filing UUID:32b6f3a6-3691-4420-a557-efcc94e5d3a9
Registrant ID:5357
Client ID:65060
2025-03-18
FOLEY & LARDNER LLP
ASSOCIATION FOR ACCESSIBLE MEDICINES
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues related to generic and biosimilar manufacturing and pharmaceutical trade.; Issues related to generic and biosimilar manufacturing and pharmaceutical trade.; Issues related to generic and biosimilar manufacturing and pharmaceutical trade.
Registered Lobbyists (1)
JOHN STROM ●NEW— Senior Counsel - U.S. House Cmte on Energy & Commerce; Counsel - U.S. Senate Cmte on Health, Education, Labor, and Pensions; Associate General Counsel - U.S. Dept of Health and Human Services; Senior Counsel - U.S. House Cmte on Natural Resources
IDs
Filing UUID:06ab37ab-2a40-472a-a6bf-37b492e6c285
Registrant ID:15042
Client ID:64990
2025-03-17
DLA PIPER LLP (US)
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.; Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.; Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.; Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.; Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.; Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
Registered Lobbyists (4)
KARINA LYNCH ●NEWMARGARET MARTIN ●NEW— Senior FDA Policy Advisor, Senate Health, Education, Labor and Pensions Committee; Health Policy Assistant, Sen. Richard BurrRACHEL PORTMAN ●NEW— Deputy Health Policy Director, Committee on Senate Health, Education, Labor and Pensions; Health Policy Assistant, Sen. Richard Burr; Intern, Rep. Robert PortmanRICHARD BURR ●NEW— U.S. Senator
Various issues facing the healthcare industry, including drug development regulation, health insurance regulation, and pharmaceutical industry regulation.; Various issues facing the healthcare industry, including drug development regulation, health insurance regulation, and pharmaceutical industry regulation.; Various issues facing the healthcare industry, including drug development regulation, health insurance regulation, and pharmaceutical industry regulation.
Registered Lobbyists (1)
TUCKER BROWN ●NEW
IDs
Filing UUID:84dfd032-4f0b-428d-80d5-a036d0d22800
Registrant ID:401109366
Client ID:64922
2025-03-14
CHECKMATE GOVERNMENT RELATIONS
GSK
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Focused engagement with HHS regarding pharmaceutical technology.; Focused engagement with HHS regarding pharmaceutical technology.
Registered Lobbyists (2)
CHARLES MCDOWELL ●NEWFREDERICK VAUGHAN ●NEW— Principal Deputy Asst. Secretary, Treasury Dept.; Deputy Asst. Secretary, Treasury Dept.; Senior Counsel, House Financial Services Cmte.; Associate Director, The White House; Confidential Asst., Office of Management & Budget; Writer, The White House
IDs
Filing UUID:551cb098-e8b9-4e86-bc01-020c8be98fc8
Registrant ID:401109039
Client ID:64838
2025-03-13
TAUZIN STRATEGIC NETWORKS
RAZORMETRICS
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Coordination with Medicaid to reduce pharmacy expenses and help improve patient outcomes
Registered Lobbyists (1)
W.J. TAUZIN ●NEW
IDs
Filing UUID:56e32462-e710-471e-80db-a25d2e4b1871
Registrant ID:400786367
Client ID:64818
2025-03-13
THORN RUN PARTNERS
BRIDGEBIO PHARMA, INC.
$30,000
$0
Filing Details
Type: ld2 • Year: 2025 Q1
Specific Issues
Issues related to the treatment of rare diseases.; Issues related to the treatment of rare diseases.
FY 2026 Appropriations for DOD and HHS, focused on funding for development and procurement of medical countermeasures and antibiotics.; FY 2026 Appropriations for DOD and HHS, focused on funding for development and procurement of medical countermeasures and antibiotics.; FY 2026 Appropriations for DOD and HHS, focused on funding for development and procurement of medical countermeasures and antibiotics.; FY 2026 Appropriations for DOD and HHS, focused on funding for development and procurement of medical countermeasures and antibiotics.
Issues related to the pharmaceutical industry.; Issues related to the pharmaceutical industry.
Registered Lobbyists (2)
MICHAEL CORCORAN ●NEWROBERT BLAIR ●NEW
IDs
Filing UUID:a8b3d74c-0214-4f8a-9cf6-b7b1f2b0d8fc
Registrant ID:401109009
Client ID:64784
2025-03-11
FORBES-TATE
ANAVEX LIFE SCIENCES
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues related to biopharmaceutical innovation
Registered Lobbyists (4)
ARTHUR SIDNEY ●NEW— LD & Chief Counsel, Rep. Jackson Lee (2008-2009); Chief of staff and chief counsel, Rep. Johnson (2009-2020)BARRETT THORNHILL ●NEW— Legislative Assistant, Sen. Mike Crapo (2003-2006)RICHARD LOPEZ ●NEWWESLEY WELCH ●NEW— Legislative Director, Sen. Richard Shelby (2005-2007); Legislative Assistant, Sen. Richard Shelby (2002-2005)
Equitable Access to Community Pharmacist Services Act; proposals to reform domestic and international tax structures; infant formula; Equitable Access to Community Pharmacist Services Act; proposals to reform domestic and international tax structures; infant formula; Equitable Access to Community Pharmacist Services Act; proposals to reform domestic and international tax structures; infant formula; Equitable Access to Community Pharmacist Services Act; proposals to reform domestic and international tax structures; infant formula
Registered Lobbyists (5)
CHANDA BETOURNEY ●NEW— Dep. Staff Director and Chief Counsel, Senate Appropriations Cmt; Chief Counsel Civil Law and Oversight, Sen. Counsel, Sen. Judiciary Cmt; Leg Asst. and Projects Dir., Leg. Corresp., Senator LeahyCHRISTOPHER BUKI ●NEW— Staff Assistant/Legislative Correspondent, Representative John Culberson; Legislative Assistant/Senior Legislative Assistant, Representative Bill Shuster; Legislative Director/Deputy Chief of Staff, Representative David McKinleyKRISTI REMINGTON ●NEW— Deputy Assistant Attorney General, US Department of Justice; Senior Counsel, House Government Reform CommitteeMARTIN REISER ●NEW— Policy Director, Republican Whip Steve Scalise, professional staff House Ways and Means Committee, Chief of Staff, Rep. Dan Miller, Budget Associate, House Budget CommitteeMATT BRAVO ●NEW— Director of Floor Operations for Maj. Whip Steve Scalise; Prof Staff, E&C; Floor Asst to Maj. Leader Eric Cantor
IDs
Filing UUID:33945617-b9a6-4b74-ad05-03e37b2255e3
Registrant ID:400774330
Client ID:64754
2025-03-09
LMH STRATEGIC SOLUTIONS
ALNYLAM PHARMACEUTICALS, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Home Infusions Issues.
Registered Lobbyists (1)
ALANNA TEMME ●NEW— Legislative Director, U.S. Representative Jon Porter
IDs
Filing UUID:2f0b7936-311f-42dc-aa4c-5f395aecb568
Registrant ID:401108183
Client ID:64726
2025-03-07
THEGROUP DC, LLC
CVS HEALTH (AND SUBSIDIARIES)
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues related to pharmacy services and other health issues.; Issues related to pharmacy services and other health issues.
Registered Lobbyists (2)
ESTEFANIA RODRIGUEZ ●NEW— Sr. Legis. Assistant, November 2017-September 2018, Rep. Barragan.KWABENA NSIAH ●NEW— Congressional Black Caucus, Policy Director; Rep. Richmond, Chief of Staff.
IDs
Filing UUID:cf634968-1c9d-4054-8284-a10305953a6f
Registrant ID:401103834
Client ID:64697
2025-03-07
CAPITOL COUNSEL LLC
ALNYLAM PHARMACEUTICALS, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development.
Registered Lobbyists (2)
JEFFREY CARROLL ●NEW— Staff Director House Energy and Commerce Committee; Chief of Staff, Rep. Frank Pallone.JOHN MARTIN ●NEW— Associate Commissioner, FDA; Legislative Director, Sen. Tom Cotton; Legislative Assistant; Sen. Tom Cotton; Legislative Assistant, Representative Tom Cotton.
IDs
Filing UUID:6a6c0fb1-21e4-4ec7-8477-0e76589a89b4
Registrant ID:313715
Client ID:64701
2025-03-07
CAPITOL COUNSEL LLC
ALNYLAM PHARMACEUTICALS, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development.
Registered Lobbyists (2)
JEFFREY CARROLL ●NEW— Staff Director House Energy and Commerce Committee; Chief of Staff, Rep. Frank Pallone.JOHN MARTIN ●NEW— Associate Commissioner, FDA; Legislative Director, Sen. Tom Cotton; Legislative Assistant; Sen. Tom Cotton; Legislative Assistant, Representative Tom Cotton.
IDs
Filing UUID:6ef1892c-d10b-43af-894c-a7cc9fd7a01d
Registrant ID:313715
Client ID:64701
2025-03-05
MEDSECUREAN.COM
INDIAN PHARMACEUTICAL ALLIANCE(FORMERLY INDIAN PHARMACEUTICAL ASSOCIATION)
$15,000
$0
Filing Details
Type: ld2 • Year: 2025 Q1
Specific Issues
The Indian Pharmaceutical Alliance (IPA) is dedicated to ensuring a level playing field in the U.S. pharmaceutical market and upholding the principles of the U.S. Hatch-Waxman Act to balance innovation with access. IPA members supply nearly 50% of Medicare Prescriptions, and of the top 10 U.S. therapeutic categories, the companies supply more than half of the prescriptions for 5 of the top 10 categories-ranging up to 60%. IPA members seek to explore U.S. - India supply chain resiliency partnership, and address affordable medicine sustainability reform measures. IPA actively supports targeted reforms to enhance the sustainability of the generic drug industry. Specifically, IPA advocates for substantial reforms of Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs) to ensure transparent pricing and fair market practices that benefit consumers. Additionally, IPA champions efforts to close loopholes in the Hatch-Waxman Act that delay generic drug entry, facilitating timely access to affordable medications. These reforms are crucial for maintaining industry sustainability, reducing healthcare costs, and ensuring that effective, affordable treatment options remain accessible to all Americans. IPAs efforts underscore its pivotal role in promoting a healthy future for all Americans through enhanced access to affordable medicine and a robust, enduring pharmaceutical industry.; Indian Pharmaceutical Alliance is a trade association in India, representing key innovative and affordable medicine manufacturers. These manufacturers supply nearly 50% of Medicare Prescriptions, and of the top 10 U.S. therapeutic categories, the companies supply more than half of the prescriptions for 5 of the top 10 categories-ranging up to 60%. IPA members seek to explore U.S. - India supply chain resiliency partnership, and address affordable medicine sustainability reform measures.; The Indian Pharmaceutical Alliance (IPA) actively supports targeted reforms in the U.S. healthcare system to ensure the sustainability of the generic drug industry. IPA advocates for meaningful reforms of Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs) to secure transparent pricing and equitable market practices that directly benefit consumers. Moreover, IPA champions efforts to close loopholes in the Hatch-Waxman Act that impede timely generic drug market entry from remving patent thickets to generic first policies. These strategic initiatives are crucial for maintaining industry sustainability, reducing U.S. healthcare costs, and ensuring that effective, affordable treatment options remain accessible to all Americans. IPAs commitment to these reforms underscores its dedication to fostering a robust and enduring U.S.generic drug sector.
Government Entities
Commerce, Dept of (DOC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office, Natl Economic Council (NEC), Natl Security Council (NSC), Centers For Medicare and Medicaid Services (CMS)
Registered Lobbyists (1)
KATHLEEN JAEGER ●NEW
IDs
Filing UUID:e0df904c-d6d1-4144-8b37-f405d3beb9e3
Registrant ID:401108536
Client ID:60141
2025-02-28
CLARK HILL PUBLIC STRATEGIES LLC
WEST PHARMACEUTICAL SERVICES, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Matters relating to tariffs, pharmaceuticals, and the medical industry.; Matters relating to tariffs, pharmaceuticals, and the medical industry.; Matters relating to tariffs, pharmaceuticals, and the medical industry.
Registered Lobbyists (1)
ANTHONY CAMPAU ●NEW— Chief of Staff and Counselor, Office of Information and Regulatory Affairs (OIRA), U.S. Office of Management and Budget (OMB), Executive Office of the President (EOP); Transition Staff, OMB/OIRA; Regulatory Reform Team, Presidential Transition Team.
IDs
Filing UUID:20357dfd-3f25-4c28-b09f-973711775d29
Registrant ID:401106670
Client ID:64539
2025-02-27
FORWARD GLOBAL
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Pharmacy Benefit Managers (PBM) provisions to be included in potential congressional legislation, including but not limited to the Continuing Resolution; engagement with the Trump Administration, including but not limited to, the Office of Public Engagement, Domestic Policy Council, and Department of Health and Human Services; Pharmacy Benefit Managers (PBM) provisions to be included in potential congressional legislation, including but not limited to the Continuing Resolution; engagement with the Trump Administration, including but not limited to, the Office of Public Engagement, Domestic Policy Council, and Department of Health and Human Services; Pharmacy Benefit Managers (PBM) provisions to be included in potential congressional legislation, including but not limited to the Continuing Resolution; engagement with the Trump Administration, including but not limited to, the Office of Public Engagement, Domestic Policy Council, and Department of Health and Human Services
Registered Lobbyists (6)
AMAN TUNE ●NEWLEAH CHARETTE ●NEWLIZZY IRWIN ●NEWMICHAEL RUBINO ●NEW— Senior Advisor to the Secretary, Health and Human ServicesNOE GARCIA ●NEW— Senior Policy Advisor, Senate Majority Leader, Bill Frist; Associate Political Director, The White House; Senior Advisor, Public Affairs, US Treasury Department; Public Liaison, US Treasury Department; Legislative Assistant, Rep. Kay HutchisonTHOMAS MATHIASEN ●NEW
IDs
Filing UUID:1faa8bea-9c34-4cdb-838d-73464ee8ccd2
Registrant ID:401105597
Client ID:64514
2025-02-24
SALT POINT STRATEGIES
VERTEX PHARMACEUTICALS
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Non-opioid pain relief and drug pipeline issues.
Registered Lobbyists (1)
ADAM BUCKALEW ●NEW— Covered Official Positions Continued: Deputy Chief of Staff, U.S. Rep. Markwayne Mullin (R-OK); Communications Director & Legislative Assistant, U.S. Rep. Gregg Harper (R-MS)